Analystreport

KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $22.00 to $21.00. They now have a "buy" rating on the stock.

Kala Pharmaceuticals, Inc.  (KALA) 
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kalarx.com